ROADSTER 2试验中经颈动脉血运重建(TCAR)术后一年结局
ROADSTER 2是一项前瞻性、开放标签、单臂、多中心上市后注册研究,纳入155例颈动脉狭窄且外科高危患者,评估TCAR术后1年安全性和有效性。结果显示围术期无心肌梗死或卒中,1年内无同侧卒中,4例(2.6%)非神经性死亡,技术成功率98.7%,颅神经损伤率1.3%。
要点
- TCAR在高危颈动脉狭窄患者中1年同侧卒中发生率为0。
- 围术期无心肌梗死或卒中,技术成功率98.7%,颅神经损伤率1.3%。
- 1年死亡4例(2.6%),均为非神经性原因。
核心结论
- 在高危因素患者中,TCAR技术成功率高,1年卒中和死亡率低。
- 需要进一步开展与颈动脉内膜剥脱术(CEA)的对比研究。
研究设计与样本
- ROADSTER 2为前瞻性、开放标签、单臂、多中心上市后注册研究。
- 2016年6月至2018年11月,美国21个中心及欧盟1个中心共纳入155例患者,为整体试验的一个亚组。
- 所有患者均被认为外科高危,接受独立神经学评估及长期临床随访。
主要发现
- 无症状患者119例(77%),有症状患者36例(23%);高危解剖因素占43%,生理因素占32%,合并因素占25%。
- 围术期无患者发生心肌梗死或卒中。
- 1年内无患者发生同侧卒中;4例患者死亡(2.6%),均死于非神经性原因。
- 技术成功率为98.7%,颅神经损伤率低至1.3%。
关键数值与推荐
- 主要终点为使用ENROUTE经颈动脉支架系统治疗后同侧卒中的发生率。
- 次要终点包括卒中、死亡和围术期心肌梗死的单独/复合发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Transcarotid artery revascularization (TCAR) is a carotid stenting technique that utilizes reversal of cerebral arterial flow to confer cerebral protection. Although carotid endarterectomy (CEA) remains the standard for treatment of symptomatic and asymptomatic carotid stenosis, the search for the optimal minimally invasive option for the high-risk surgical patient continues. The goal of the current study is to evaluate the 1-year safety and efficacy of TCAR in a prospective clinical trial. METHODS: ROADSTER 2 is a prospective, open-label, single-arm, multicenter, post-approval registry for patients undergoing TCAR. All patients were considered high risk for CEA and underwent independent neurological assessments preoperatively, postoperatively, and had long-term clinical follow-up. The primary end point was incidence of ipsilateral stroke after treatment with the ENROUTE Transcarotid Stent System. Secondary end points included individual/composite rates of stroke, death, and perioperative myocardial infarction. RESULTS: Between June 2016 and November 2018, 155 patients at 21 centers in the United States and one in the European Union were enrolled and represented a subset of the overall trial. Asymptomatic (n = 119; 77%) and symptomatic patients (n = 36; 23%) with high-risk anatomic (ie, high lesion, restenosis, radiation injury; 43%), physiologic (32%), or combined factors (25%) were enrolled. No patient suffered a perioperative myocardial infarction or stroke. Over the year, no patient had an ipsilateral stroke, but four patients died (2.6%), all from non-neurological causes. Additionally, a technical success rate of 98.7% with a low cranial nerve deficit rate of 1.3% was achieved. CONCLUSIONS: In patients with high risk factors, TCAR yields high technical success with a low stroke and death rate at 1 year. Further comparative studies with CEA are warranted.
引用
- Kashyap VS, So KL, Schneider PA, et al. One-year outcomes after transcarotid artery revascularization (TCAR) in the ROADSTER 2 trial. J Vasc Surg. 2022. PMID: 35381327. doi:10.1016/j.jvs.2022.03.872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。